Clinical Data GSK hails ‘unprecedented’ cure rates with hep B drug PharmaphorumThe B-Well trials of GSK's bepirovirsen position the antisense drug as a "major step towards a cure for hepatitis B infection," according to experts.Infectious DiseaseRead full story pharminent May 28, 2026 (Last updated: May 28, 2026) Pharmaphorum The B-Well trials of GSK’s bepirovirsen position the antisense drug as a “major step towards a cure for hepatitis B infection,” according to experts. Infectious Disease Read full story Post navigation Previous: AbbVie snags FDA’s first ADC approval for ultra-rare blood cancerNext: France ‘first EU country to cover obesity drugs’ Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
